Samjin Pharmaceutical삼진제약
005500 · KOSPI · ₩005500 · 삼진제약
- Market cap
- ₩257B
- Enterprise value
- ₩264B
- P/E
- 11.8×
- P/B
- 0.9×
- Dividend yield
- 4.1%
- ROE
- 7.3%
- Net margin
- 7.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−25.4% from the high
₩16,580Today: ₩19,200 – ₩19,490₩25,900
Returns
- 1W+0.6%
- 1M+4.7%
- 3M+10.1%
- 6M+0.8%
- YTD−2.2%
- 1Y−3.0%
- Volume today
- 36,456
- 1.1× the 20-day average
- Traded today
- ₩705M
- Listed shares
- 13,320,000
- EPS (12 months)
- ₩1,642
- Earnings yield 8.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat4.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Samjin Pharmaceutical stock overview
Samjin Pharmaceutical (삼진제약, KRX: 005500) is listed on KOSPI, in the Biotech & Pharma sector. The company develops, manufactures, and sells pharmaceuticals in Korea, spanning over-the-counter medicines such as the painkiller Gebolin and appetite stimulant Tresstan, prescription drugs for chronic conditions such as the antithrombotic Plavix and brain function improver Newtrin, and active pharmaceutical ingredients. Its shares closed at ₩19,310 on Oct 27, 2026, up 0.78% on the day, giving it a market value of ₩257B.
Key facts
- Market cap
- ₩257B
- Sector
- Biotech & Pharma
- Latest price change
- +0.78%
- As of
- Oct 27, 2026
- Main business
- The company develops, manufactures, and sells pharmaceuticals in Korea, spanning over-the-counter medicines such as the painkiller Gebolin and appetite stimulant Tresstan, prescription drugs for chronic conditions such as the antithrombotic Plavix and brain function improver Newtrin, and active pharmaceutical ingredients.
Quick answers about Samjin Pharmaceutical
- What does Samjin Pharmaceutical do?
- The company develops, manufactures, and sells pharmaceuticals in Korea, spanning over-the-counter medicines such as the painkiller Gebolin and appetite stimulant Tresstan, prescription drugs for chronic conditions such as the antithrombotic Plavix and brain function improver Newtrin, and active pharmaceutical ingredients. It is also expanding into health functional foods, cosmetics, and medical devices, and is researching new drugs for conditions including cancer, dementia, and diabetes. Its manufacturing sites are the Hyangnam and Osong facilities.
- What is the market cap of Samjin Pharmaceutical?
- The market capitalisation of Samjin Pharmaceutical was ₩257B at the close on Oct 27, 2026.
- Who are the largest shareholders of Samjin Pharmaceutical?
- According to the latest official filings, the largest reported holders are Jo Ui-hwan (13.41%, as of Aug 10, 2026); Choi Ji-hyun (10.31%, as of Sep 2, 2026); Jo Gyu-seok (4.20%, as of Aug 10, 2026).
- When is the next earnings report from Samjin Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Samjin Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Samjin Pharmaceutical?
- Yes. The National Pension Service held 2.05% of Samjin Pharmaceutical shares as of Dec 31, 2025.
Company profile
The company develops, manufactures, and sells pharmaceuticals in Korea, spanning over-the-counter medicines such as the painkiller Gebolin and appetite stimulant Tresstan, prescription drugs for chronic conditions such as the antithrombotic Plavix and brain function improver Newtrin, and active pharmaceutical ingredients. It is also expanding into health functional foods, cosmetics, and medical devices, and is researching new drugs for conditions including cancer, dementia, and diabetes. Its manufacturing sites are the Hyangnam and Osong facilities.
Written by AI from the company's latest annual report.
- Korean name
- 삼진제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 최지현, 조규석
- Founded
- Apr 1968
- Listed
- Jun 1988
- Listed shares
- 13,320,000
- Fiscal year ends
- Month 12
- Website
- www.samjinpharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Insider shareholding reportSep 2, 2026
- 5%+ holding reportSep 2, 2026
- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
- Insider shareholding reportAug 25, 2026
Titles in Korean until English translations are added.
Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500
Source: KRX statistical information